Compare CVNA & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVNA | INSM |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0B | 41.2B |
| IPO Year | 2017 | 2000 |
| Metric | CVNA | INSM |
|---|---|---|
| Price | $447.42 | $163.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 22 |
| Target Price | ★ $442.45 | $187.30 |
| AVG Volume (30 Days) | ★ 4.0M | 3.9M |
| Earning Date | 02-18-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.40 | N/A |
| Revenue | ★ $18,266,000,000.00 | $447,022,000.00 |
| Revenue This Year | $48.93 | $49.51 |
| Revenue Next Year | $27.67 | $134.47 |
| P/E Ratio | $100.80 | ★ N/A |
| Revenue Growth | ★ 45.55 | 30.34 |
| 52 Week Low | $148.25 | $60.40 |
| 52 Week High | $485.33 | $212.75 |
| Indicator | CVNA | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 54.23 | 35.08 |
| Support Level | $450.76 | $168.01 |
| Resistance Level | $474.50 | $186.74 |
| Average True Range (ATR) | 18.05 | 6.42 |
| MACD | -1.16 | -1.12 |
| Stochastic Oscillator | 67.72 | 13.93 |
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.